• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

去唾液酸糖蛋白受体介导的肝肿瘤靶向载药系统研究进展

高媛悦, 刘爱赟, 沈佳佳, 丁娅

高媛悦, 刘爱赟, 沈佳佳, 丁娅. 去唾液酸糖蛋白受体介导的肝肿瘤靶向载药系统研究进展[J]. 中国药科大学学报, 2016, 47(5): 537-542. DOI: 10.11665/j.issn.1000-5048.20160505
引用本文: 高媛悦, 刘爱赟, 沈佳佳, 丁娅. 去唾液酸糖蛋白受体介导的肝肿瘤靶向载药系统研究进展[J]. 中国药科大学学报, 2016, 47(5): 537-542. DOI: 10.11665/j.issn.1000-5048.20160505
GAO Yuanyue, LIU Aiyun, SHEN Jiajia, DING Ya. Advances in asialoglycoprotein receptor-mediated liver cancer targeted drug delivery system[J]. Journal of China Pharmaceutical University, 2016, 47(5): 537-542. DOI: 10.11665/j.issn.1000-5048.20160505
Citation: GAO Yuanyue, LIU Aiyun, SHEN Jiajia, DING Ya. Advances in asialoglycoprotein receptor-mediated liver cancer targeted drug delivery system[J]. Journal of China Pharmaceutical University, 2016, 47(5): 537-542. DOI: 10.11665/j.issn.1000-5048.20160505

去唾液酸糖蛋白受体介导的肝肿瘤靶向载药系统研究进展

基金项目: 国家自然科学基金资助项目(No.31470916,No.31500769);药物质量与安全预警教育部重点实验室开放课题资助项目(No.DQCP2015MS01)

Advances in asialoglycoprotein receptor-mediated liver cancer targeted drug delivery system

  • 摘要: 去唾液酸糖蛋白受体(asialoglycoprotein receptor,ASGPR)是一种主要表达在肝窦状隙和基底外侧细胞表面的受体,它能专一性识别、结合并内吞末端具有半乳糖或乙酰氨基半乳糖残基的去唾液酸糖蛋白类物质。基于这一特性,ASGPR受体介导的肝肿瘤靶向治疗引起了研究者们的广泛关注。本文从糖基化前药、小分子纳米药物载体和糖基化基因复合物3个方面对近3年来该领域的最新研究进展进行综述。
    Abstract: Asialoglycoprotein receptor(ASGPR)is a receptor expressed mainly on the surface of liver sinusoidal and basolateral cells. It can exclusively identity, combine and clear desialylated glycoproteins with exposed non-reducing D-galactose(Gal)or nacetylgalactosamine(GalNAc)as end groups. Based on this characteristic, ASGPR-mediated targeted liver cancer therapy has drawn extensive attention. The present review details the latest research progress of this field in three aspects, glycosylated prodrug, small molecular nanocarriers, and glycosylated gene complex therapy system.
  • [1] Singh GK,Siahpush M,Altekruse SF.Time trends in liver cancer mortality,incidence,and risk factors by unemployment level and race/ethnicity,United States,1969-2011[J].J Community Health,2013,38(5):926-940.
    [2] Stockert RJ.The asialoglycoprotein receptor:relationships between structure,function,and expression[J].Physiol Rev,1995,75(3):591-610.
    [3] Ma Y,Chen H,Su S,et al.Galactose as broad ligand for multiple tumor imaging and therapy[J].J Cancer,2015,6(7):658-670.
    [4] Lu L, Guo Y, Xu L, et al. Galactosylation of caffeic acid by an engineered β-galactosidase[J]. Drug Discov Ther,2015,9(2):123-128.
    [5] Singh Y,Palombo M,Sinko PJ.Recent trends in targeted anticancer prodrug and conjugate design[J].Curr Med Chem,2008,15(18):1802-1826.
    [6] Fiume L,Mattioli A,Balboni PG,et al.Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin[J].FEBS Lett,1979,103(1):47-51.
    [7] Muro S.Challenges in design and characterization of ligand-targeted drug delivery systems[J].J Control Release,2012,164(2):125-137.
    [8] Fiume L,Mattioli A,Busi C,et al.Selective penetration and pharmacological activity of lactosaminated albumin conjugates of adenine arabinoside 5-monophosphate(ara-AMP)in mouse liver[J].Gut,1984,25(12):1392-1398.
    [9] Wang J,Wu W,Zhang Y,et al.The combined effects of size and surface chemistry on the accumulation of boronic acid-rich protein nanoparticles in tumors[J].Biomaterials,2014,35(2): 866-878.
    [10] Dodeur M,Durand D,Dumont J,et al.Effects of streptozotocin-induced diabetes mellitus on the binding and uptake of asialoorosomucoïd by isolated hepatocytes from rats[J].Eur J Biochem, 1982,123(2):383-387.
    [11] Hillaireau H,Couvreur P.Nanocarriers′ entry into the cell:relevance to drug delivery[J].Cell Mol Life Sci,2009,66(17):2873-2896.
    [12] Zou Y, Song Y, Yang W, et al. Galactose-installed photo-crosslinked pH-sensitive degradable micelles for active targeting chemotherapy of hepatocellular carcinoma in mice[J].J Control Release,2014,193:154-161.
    [13] Zhong Y,Yang W,Sun H,et al.Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells[J]. Biomacromolecules,2013,14(10):3723-3730.
    [14] Chen W,Meng F,Cheng R,et al.Biodegradable glycopolymer-b-poly(ε-caprolactone)block copolymer micelles: versatile construction,tailored lactose functionality,and hepatoma-targeted drug delivery[J].J Mater Chem B,2015,3(11):2308-2317.
    [15] Schettini DA,Ribeiro RR,Demicheli C,et al.Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size[J].Int J Pharm,2006,315(1):140-147.
    [16] Zhang H,Xiao Y,Cui S,et al.Novel galactosylated poly(ethylene glycol)-cholesterol for liposomes as a drug carrier for hepatocyte-rargeting[J].J Nanosci Nanotechnol,2015,15(6): 4058-4069.
    [17] Pathak PO, Nagarsenker MS, Barhate CR, et al. Cholesterol anchored arabinogalactan for asialoglycoprotein receptor targeting:synthesis,characterization,and proof of concept of hepatospecific delivery[J].Carbohyd Res,2015,408:33-43.
    [18] Villa R,Cerroni B,Viganò L,et al.Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells[J].Colloids Surf B Biointerfaces, 2013,110:434-442.
    [19] Lundquist JJ,Toone EJ.The cluster glycoside effect[J].Chem Rev,2002,102(2):555-578.
    [20] She W,Pan D,Luo K,et al.PEGylated dendrimer-doxorubicin cojugates as pH-sensitive drug delivery systems:synthesis and in vitro characterization[J].J Biomed Nanotechnol,2015,11(6): 964-978.
    [21] Duncan B,Kim C,Rotello VM.Gold nanoparticle platforms as drug and biomacromolecule delivery systems[J].J Control Release,2010,148(1):122-127.
    [22] Ding Y,Liang JJ,Geng DD,et al.Development of a liver-targeting gold-PEG-galactose nanoparticle platform and a structure-function study[J].Part Part Syst Char,2014,31(3): 347-356.
    [23] Zhang Y,Chen T,Yuan P,et al.Encapsulation of honokiol into self-assembled pectin nanoparticles for drug delivery to HepG2 cells[J].Carbohydr Polym,2015,133:31-38.
    [24] Ding Y,Bao L,Zhang WJ.Preparation and photocatalytic property of magnetic Fe3O4-TiO2 nanoparticles with a core-shell structure[J].J China Pharm Univ(中国药科大学学报),2010,41(4):312-316.
    [25] An J,Zhang X,Guo Q,et al.Glycopolymer modified magnetic mesoporous silica nanoparticles for MR imaging and targeted drug delivery[J].Colloids Surf A Physicochem Eng Asp,2015,482:98-108.
    [26] Xiao B,Wang X,Qiu Z,et al.A dual-functionally modified chitosan derivative for efficient liver-targeted gene delivery[J].J Biomed Mater Res A,2013,101(7):1888-1897.
    [27] Thapa B, Kumar P, Zeng H, et al. Asialoglycoprotein receptor-mediated gene delivery to hepatocytes using galactosylated polymers[J].Biomacromolecules,2015,16(9):3008-3020.
    [28] Devarasu T,Saad R,Ouadi A,et al.Potent calcium phosphate nanoparticle surface coating for in vitro and in vivo siRNA delivery:a step toward multifunctional nanovectors[J].J Mater Chem B, 2013,1(36):4692-4700.
    [29] Han L,Tang C,Yin C.Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy[J].Biomaterials,2014,35(15):4589-4600.
    [30] Sajeesh S,Lee TY,Kim JK,et al.Efficient intracellular delivery and multiple-target gene silencing triggered by tripodal RNA based nanoparticles:a promising approach in liver-specific RNAi delivery[J].J Control Release,2014,196:28-36.
计量
  • 文章访问数: 
  • HTML全文浏览量:  0
  • PDF下载量: 
  • 被引次数: 0
出版历程
  • 刊出日期:  2016-10-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭